Cosmo Pharmaceuticals Launches Winlevi® in Singapore and Malaysia, Expanding Acne Treatment in Southeast Asia

Reuters
07/17
Cosmo Pharmaceuticals Launches Winlevi® in Singapore and Malaysia, Expanding Acne Treatment in Southeast Asia

Cosmo Pharmaceuticals N.V. has announced the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its entry into Southeast Asia through a partnership with Hyphens Pharma International Limited. This topical treatment for acne vulgaris is aimed at patients aged twelve and older. The collaboration is part of Cosmo's strategy to expand its global reach and address the increasing demand for advanced acne care in the region. This launch is a significant step towards offering innovative dermatology solutions and improving the quality of life for millions affected by acne.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmo Pharmaceuticals NV published the original content used to generate this news brief on July 17, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10